Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Reva Basho
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04512261CT.gov TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Central Nervous System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | Reva Basho | P1/2 | CCC · 48 |
| 3-N-BUTYLPHTHALIDE | Qianfoshan Hospital | P4 | BB |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | BB |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | BB |
| Donanemab | Eli Lilly and Company | P3 | BB |
| Encenicline | FORUM Pharmaceuticals Inc | P2 | BB |
| 2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE | Taichung Veterans General Hospital | P4 | B |
| Levodopa | Merck Sharp & Dohme LLC | P2 | B |
| Dexasone | Eli Lilly and Company | P3 | B |
+42 more in the Central Nervous System Disorder cohort
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab in Central Nervous System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-central-nervous-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →